Showing results (101-110 of 111) with videos related to
Sort By:
Pageof 12
Proteins|October 25, 2011
Target highlights in CASP9: Experimental target structures for the critical assessment of techniques for protein structure predictionAndriy Kryshtafovych, John Moult, Sergio G Bartual, et al.Protein Science : a Publication of the Protein Society|August 22, 2015
A community resource of experimental data for NMR / X-ray crystal structure pairsJohn K Everett, Roberto Tejero, Sarath B K Murthy, et al.The Journal of Clinical Investigation|August 16, 2021
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemiaWeimin Kong, Alexander Dimitri, Wenliang Wang, et al.Mbio|February 8, 2022
SARS-CoV-2 Variants Associated with Vaccine Breakthrough in the Delaware Valley through Summer 2021Andrew D Marques, Scott Sherrill-Mix, John K Everett, et al.Nature Medicine|January 29, 2020
Lentiviral gene therapy for X-linked chronic granulomatous diseaseDonald B Kohn, Claire Booth, Elizabeth M Kang, et al.Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.Nature Medicine|January 9, 2023
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trialDavid S Hong, Brian A Van Tine, Swethajit Biswas, et al.Science Advances|November 13, 2024
TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell functionAlexander J Dimitri, Amy E Baxter, Gregory M Chen, et al.Blood|July 21, 2023
Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndromeRoxane Labrosse, Julia I Chu, Myriam A Armant, et al.Nature Medicine|January 15, 2026
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.Pageof 12